Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004985 · ClinicalTrials.gov registry record · Phase 2
Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy
A Phase 2 study, sponsored by Agouron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00004985 is a Phase 2 study that has completed, run by Agouron Pharmaceuticals. The registered enrollment target is 75 participants.
The verdict
NCT00004985, a Phase 2 study, has completed, sponsored by Agouron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to look at the effectiveness of an anti-HIV drug combination that adds capravirine in patients who have failed their first drug combination treatment.
Interventions
- DRUG Nelfinavir mesylate
- DRUG Capravirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2000-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004985
The ClinicalTrials.gov registry entry for NCT00004985 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agouron Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nelfinavir mesylate is the first listed.
NCT00004985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004985 about?
NCT00004985 is a clinical study titled "Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy". The purpose of this study is to look at the effectiveness of an anti-HIV drug combination that adds capravirine in patients who have failed their first drug combination treatment.
What is the current status of trial NCT00004985?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2000-01.
What interventions are being tested in trial NCT00004985?
The interventions under investigation include: Nelfinavir mesylate (DRUG), Capravirine (DRUG).
Who is sponsoring clinical trial NCT00004985?
This trial is sponsored by Agouron Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.